XML 42 R6.htm IDEA: XBRL DOCUMENT v2.4.1.9
CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)
In Thousands, unless otherwise specified
12 Months Ended
Dec. 31, 2014
Dec. 31, 2013
Cash flows used in operating activities:    
Net loss: $ (11,061)us-gaap_NetIncomeLoss $ (8,817)us-gaap_NetIncomeLoss
Adjustments to reconcile net loss to net cash used in operating activities:    
Stock-based compensation expense 2,565us-gaap_ShareBasedCompensation 1,370us-gaap_ShareBasedCompensation
Depreciation 363us-gaap_Depreciation 158us-gaap_Depreciation
Changes in operating assets and liabilities:    
Increase in related party receivables (5)us-gaap_IncreaseDecreaseInDueFromRelatedPartiesCurrent (22)us-gaap_IncreaseDecreaseInDueFromRelatedPartiesCurrent
Increase in non-trade receivables (5)us-gaap_IncreaseDecreaseInOtherReceivables 0us-gaap_IncreaseDecreaseInOtherReceivables
Increase in inventories (169)us-gaap_IncreaseDecreaseInInventories (38)us-gaap_IncreaseDecreaseInInventories
Decrease (increase) in prepaid expenses 104us-gaap_IncreaseDecreaseInPrepaidExpense (421)us-gaap_IncreaseDecreaseInPrepaidExpense
Increase in accounts payable 126us-gaap_IncreaseDecreaseInAccountsPayable 65us-gaap_IncreaseDecreaseInAccountsPayable
(Decrease) increase in related party payable (74)us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent 90us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent
Increase (decrease) in accrued and other current liabilities 163us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities (71)us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
Net cash used in operating activities (7,993)us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations (7,686)us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
Cash flows used in investing activities:    
Additions to property, plant and equipment (1,164)us-gaap_PaymentsToAcquirePropertyPlantAndEquipment (295)us-gaap_PaymentsToAcquirePropertyPlantAndEquipment
Net cash used in investing activities (1,164)us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations (295)us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
Cash flows from financing activities:    
Proceeds from funding provided by Harvard Bioscience, Inc. 0hart_ProceedsFromInvestmentMadeByParentCompany 21,986hart_ProceedsFromInvestmentMadeByParentCompany
Proceeds from issuance of common stock 420us-gaap_ProceedsFromIssuanceOfCommonStock 3us-gaap_ProceedsFromIssuanceOfCommonStock
Net cash provided by financing activities 420us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations 21,989us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
Effect of exchange rate changes on cash 1us-gaap_EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations 0us-gaap_EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations
Net (decrease) increase in cash (8,736)us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease 14,008us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease
Cash at the beginning of the period 14,008us-gaap_CashAndCashEquivalentsAtCarryingValue 0us-gaap_CashAndCashEquivalentsAtCarryingValue
Cash at the end of the period $ 5,272us-gaap_CashAndCashEquivalentsAtCarryingValue $ 14,008us-gaap_CashAndCashEquivalentsAtCarryingValue